Skip to main content

Table 3 Therapeutic regimens

From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

Regimens Dose Days of administration
R-HyperCVAD regimen   
 Cycle A   
  Rituximab 375 mg/m2 1
  Cyclophosphamide 300 mg/m2 every 12 h 2–4
  Vincristine 1.4 mg/m2 4, 11
  Doxorubicin 50 mg/m2 4
  Dexamethasone 40 mg per day 1–4, 11–14
 Cycle B   
  Rituximab 375 mg/m2 1
  Methotrexate 1 g/m2 continuous intravenous infusion for 24 h 2
  Cytarabine 3 g/m2 every 12 h 3, 4
 DA-EPOCH-R regimen a   
  Rituximab 375 mg/m2 1
  Etoposide 50 mg/m2 continuous intravenous infusion for 24 h 2–5
  Doxorubicin 10 mg/m2 continuous intravenous infusion for 24 h 2–5
  Vincristine 0.4 mg/m2 continuous intravenous infusion for 24 h 2–5
  Cyclophosphamide 750 mg/m2 6
  Prednisone 60 mg/m2 2–6
DA-EPOCH-R/MA regimen   
 DA-EPOCH-R   
  Rituximab 375 mg/m2 1
  Etoposide 50 mg/m2 continuous intravenous infusion for 24 h 2–5
  Doxorubicin 10 mg/m2 continuous intravenous infusion for 24 h 2–5
  Vincristine 0.4 mg/m2 continuous intravenous infusion for 24 h 2–5
  Cyclophosphamide 750 mg/m2 6
  Prednisone 60 mg/m2 2–6
 Alternating with MA   
  Methotrexate 3 g/m2 1
  Cytarabine 2 g/m2 every 12 h 2–3
 Intrathecal prophylaxis   
  Methotrexate 10 mg  
  Dexamethasone 10 mg  
  Cytarabine 50 mg  
  1. PB-DHL primary breast double-hit lymphoma, R-HyperCVAD rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate, DA-EPOCH-R rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, DA-EPOCH-R/MA, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine, MA high-dose methotrexate and cytarabine, IV intravenous infusion
  2. aThe doses of etoposide, doxorubicin, and cyclophosphamide were adjusted according to criteria [23, 35]